Lunsekimig
Based on 1 Customer Validation
Lunsekimig (SAR443765) is a nanobody composed of 5 VH domains that targets both TSLP and IL-13. Lunsekimig blocks the functional effects of TSLP and IL-13, inhibits related inflammatory signals, and improves lung function associated with type 2 inflammation. Lunsekimig can be used in research on asthma and type 2 inflammation.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.00%
- CAS 番号: 2770858-49-4
- 分子量:69.702 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
VH-VH-VH-VH-VH
Human
|
IL-13 |
TSLP |
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
VH-VH-VH-VH-VH
ELISA, FACS, Functional assay
-
Loaded IL-13 Protein, Human (HEK293, His, HY-P70568) on NTA biosensor, can bind Lunsekimig with an affinity constant of 2.806E-09 M as determined in BLI assay. -
Loaded Serum Albumin/ALB Protein, Human (Biotinylated, HEK293, His-Avi, HY-P78077) on NTA biosensor, can bind Lunsekimig with an affinity constant of 5.297E-08 M as determined in BLI assay. -
Loaded TSLP Protein, Human (HEK293, His, HY-P70818) on HIS1K biosensor, can bind Lunsekimig with an affinity constant of <1.0E-11 M as determined in BLI assay.
化学情報
-
CAS 番号 2770858-49-4
-
性状 Liquid
-
分子量 69.702 kDa
-
Color Colorless to light yellow
-
別名
SAR443765
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Deiteren A, et al. A first-in-human, single and multiple dose study of lunsekimig, a novel anti-TSLP/anti-IL-13 NANOBODY® compound, in healthy volunteers. Clinical and translational science. 2024 Jun;17(6):e13864. [Content Brief]
[2]. Deiteren A, et al. A proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODY molecule. The European respiratory journal. 2025 Apr;65(4):2401461. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)